Loss of RUNX2 expression caused resistance to mitogen-activated protein kinase/extracellular signal-regulated kinase (MEK) inhibitors through receptor tyrosine kinases (RTKs) in CRC tumors with KRAS alterations [38]. Here, RUNX2 is linked to colorectal carcinoma.